I
Imprint Labs
Tools to decode immune memory signatures, identifying hidden causes of chronic diseases for new treatments and cures
About Imprint Labs
IMPRINT is at the forefront of forensic immunology, developing advanced tools to read and analyze immune memory signatures. The company focuses on reconstructing immune histories from memory B cells and T cells to uncover the hidden causes of chronic diseases. By unlocking and decoding this data, IMPRINT aims to identify new disease mechanisms and therapeutic targets, facilitating the development of diagnostics, cures, and treatments. Operating within the framework of Focused Research Organizations (FROs), IMPRINT pursues ambitious scientific milestones over a finite period, typically five years, to produce high-impact public goods. The company serves the scientific and medical research community, providing them with the tools necessary to advance disease treatment. IMPRINT's business model revolves around creating experimental and computational immunology tools that can be utilized by researchers and healthcare professionals to accelerate progress in understanding and treating chronic diseases.
Source: Dealroom company dataAt a glance
- Founded
- 2023
- Headquarters
- New York City, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
New York City Economic Development Corporation
Convergent Research
Merck Global Health Innovation Fund
CQDM
The Venture Collective
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Imprint Labs on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Imprint Labs on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.